Clinical Trials Logo
  1. Home
  2. Adenomatous Polyposis Coli
  3. NCT04948398
  4. Details
NCT04948398 Clinical Trial

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli Clinical Trial

Official title:
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT04948398
Other study ID # CR108964
Secondary ID CNTO1959APC4001
Status No longer available
Phase
First received
Last updated

Study information
Verified date February 2022
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

Recruitment information / eligibility

— Not specified —

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Guselkumab
Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Janssen Research & Development, LLC
See also
  Status Clinical Trial Phase
Terminated NCT00585312 - Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Phase 3
Completed NCT03095703 - Sirolimus and Familial Adenomatous Polyposis (FAP) Phase 2
Completed NCT03649971 - A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT05014360 - A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis Phase 1
Completed NCT01604564 - Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02113202 - Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Phase 1
Withdrawn NCT03027401 - Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Terminated NCT00140894 - A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Phase 4
Active, not recruiting NCT01187901 - A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Phase 2
Recruiting NCT00319007 - Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Phase 2